Compare Merck & Co., Inc. (MRK) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Abrdn Physical Platinum Shares ETF — how do they compare? Merck & Co., Inc. trades at $148.23 (market cap $366.28B), while Abrdn Physical Platinum Shares ETF trades at $16.91. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Abrdn Physical Platinum Shares ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| MRK | PPLT | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $156.43 | $25.23 |
52-Week Low | $77.60 | $12.38 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
PPLT (abrdn Platinum ETF Trust) trades at $16.46, down 0.24% with a bullish technical signal from moving averages. The ETF tracks physical platinum prices, which have lagged behind gold and silver's recent rally. Recent news highlights platinum's potential catch-up trade opportunity as price ratios suggest potential mean reversion. Technical indicators show mixed signals with neutral oscillators but strong trend strength from ADX.
The outlook suggests potential upside as platinum seeks to close its performance gap with other precious metals. Key risks include commodity price volatility and macroeconomic factors affecting industrial demand. Investment opportunity lies in platinum's historical tendency for mean reversion and its dual role as both precious metal and industrial commodity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
